203 related articles for article (PubMed ID: 12171777)
1. Thromboembolism in patients on thalidomide for myeloma.
Bowcock SJ; Rassam SM; Ward SM; Turner JT; Laffan M
Hematology; 2002 Feb; 7(1):51-3. PubMed ID: 12171777
[TBL] [Abstract][Full Text] [Related]
2. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
Radocha J; Maisnar V
Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
[TBL] [Abstract][Full Text] [Related]
3. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
[TBL] [Abstract][Full Text] [Related]
4. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide.
Koh Y; Bang SM; Lee JH; Yoon HJ; Do YR; Ryoo HM; Lee N; Kim SJ; Kim K; Yoon SS; Won JH; Mun YC; Lee MH; Rhee KH; Kim HJ; Eom H; Kim MK; Shin HC;
Ann Hematol; 2010 Feb; 89(2):201-6. PubMed ID: 19705118
[TBL] [Abstract][Full Text] [Related]
5. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
Martin MG; Vij R
Clin Lymphoma Myeloma; 2009 Aug; 9(4):320-3. PubMed ID: 19717384
[TBL] [Abstract][Full Text] [Related]
6. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
[TBL] [Abstract][Full Text] [Related]
7. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
10. Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment.
Maisnar V; Radocha J; Büchler T; Bláha V; Malý J; Hájek R
Eur J Haematol; 2007 Oct; 79(4):305-9. PubMed ID: 17803678
[TBL] [Abstract][Full Text] [Related]
11. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
12. Advantages of using thalidomide for the management of refractory myeloma patients.
Corso A; Lorenzi A; Orlandi E; Astori C; Mangiacavalli S; Lazzarino M
Haematologica; 2002 Mar; 87(3):327-8. PubMed ID: 11869949
[TBL] [Abstract][Full Text] [Related]
13. Arterial and venous thrombotic complications with thalidomide in multiple myeloma.
Alkindi S; Dennison D; Pathare A
Arch Med Res; 2008 Feb; 39(2):257-8. PubMed ID: 18164975
[No Abstract] [Full Text] [Related]
14. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Hoiczyk M; Flasshove M; Hense J; Bojko P; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2005 Jan; 74(1):40-6. PubMed ID: 15613105
[TBL] [Abstract][Full Text] [Related]
15. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
Katodritou E; Gastari V; Verrou E; Hadjiaggelidou C; Varthaliti M; Georgiadou S; Laschos K; Xirou P; Yiannaki E; Constantinou N; Markala D; Zervas K
Leuk Res; 2009 Aug; 33(8):1137-40. PubMed ID: 19250676
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
Srkalovic G; Cameron MG; Rybicki L; Deitcher SR; Kattke-Marchant K; Hussein MA
Cancer; 2004 Aug; 101(3):558-66. PubMed ID: 15274069
[TBL] [Abstract][Full Text] [Related]
17. [Single-agent thalidomide for advanced and refractory multiple myeloma].
Okikawa Y; Takimoto Y; Noda M; Imagawa J; Katayama Y; Sakai A; Okita H; Fujimura K; Kimura A
Rinsho Ketsueki; 2003 Jun; 44(6):368-74. PubMed ID: 12884814
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
Galli M; Elice F; Crippa C; Comotti B; Rodeghiero F; Barbui T
Haematologica; 2004 Sep; 89(9):1141-2. PubMed ID: 15377478
[TBL] [Abstract][Full Text] [Related]
19. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
Baz R; Li L; Kottke-Marchant K; Srkalovic G; McGowan B; Yiannaki E; Karam MA; Faiman B; Jawde RA; Andresen S; Zeldis J; Hussein MA
Mayo Clin Proc; 2005 Dec; 80(12):1568-74. PubMed ID: 16342649
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma and treatment-related thromboembolism: oncology nurses' role in prevention, assessment, and diagnosis.
Wiley KE
Clin J Oncol Nurs; 2007 Dec; 11(6):847-51. PubMed ID: 18063543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]